

# PRIOR AUTHORIZATION REQUEST FORM

Virginia Premier Anti-Migraine Preferred

Phone: 800-727-7536

Fax back to: 833-770-7569

Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

Q1. Is this request for initial or continuing therapy?

Initial therapy

Continuing therapy

Q2. For continuing therapy, please specify start date (MM/YY). If the request is for continuing therapy and the requested medication was approved by a previous Health Plan, please submit documentation of the previous approval to be considered.

Q3. Please indicate the patient's diagnosis for the requested medication:

Preventative treatment of migraine

Acute treatment of migraine

Treatment of episodic cluster headache

Other

Q4. If the patient's diagnosis is OTHER, please specify below:

Q5. Has the patient had trial and failure of two generic triptans? Please select all that apply:

Eletriptan

Naratriptan

Rizatriptan

Sumatriptan

Zolmitriptan

# PRIOR AUTHORIZATION REQUEST FORM

Virginia Premier Anti-Migraine Preferred

Phone: 800-727-7536

Fax back to: 833-770-7569

Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:

Prescriber Name:

- Other  
 None of the above

Q6. If the medication is OTHER, please specify below:

Q7. If the patient has NOT tried any of the medications listed in the previous question, is there a reason why these medications cannot be used (i.e., contraindication, history of adverse event, etc.)?

Q8. Does the member have a diagnosis of migraine with or without aura base on International Classification of Headache Disorders (ICHD-III) diagnostic criteria?

- Yes  No

Q9. For which of the following is the member using this medication? Check all that apply.

- Preventative treatment of migraine  
 Acute treatment of migraine  
 Treatment of episodic cluster headache  
 Other use

Q10. For OTHER USE, specify details:

Q11. Is the member 18 years of age or older?

- Yes  No

Q12. Can you confirm that the member does not have medication over-use headache (MOH)?

- Yes  No

Q13. If the member is a woman of childbearing age, has the member had a pregnancy test at baseline?

- Yes  No  Not applicable

Q14. Has the member tried and failed a greater than or equal to 1 month trial of any 2 of the following oral medications?

- Antidepressants (e.g., amitriptyline, venlafaxine)  
 Beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)  
 Anti-epileptics (e.g., valproate, topiramate)  
 Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (e.g., lisinopril, candesartan)

Q15. For RENEWAL, did the member demonstrated significant decrease in the number, frequency, and/or intensity of headaches?

# PRIOR AUTHORIZATION REQUEST FORM

Virginia Premier Anti-Migraine Preferred

Phone: 800-727-7536

Fax back to: 833-770-7569

Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Q16. For RENEWAL, has the member experienced an overall improvement in function with therapy?		
<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Q17. For RENEWAL, does the member continue to utilize prophylactic intervention modalities (e.g., behavioral therapy, physical therapy, life-style modification)?		
<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Q18. For RENEWAL, if the member is a woman of childbearing age, will the member continue to be monitored for pregnancy status?		
<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Not applicable
Q19. For RENEWAL, does the member have an absence of unacceptable toxicity (e.g., intolerable injection site pain or constipation)?		
<input type="checkbox"/> Yes	<input type="checkbox"/> No	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document